Brief: Dermapharm Holding Q3 Unadjusted EBITDA At EUR 208.4 Mln

Dermapharm Holding SE

15/11/2023 06:34

Nov 15 (Reuters) - Dermapharm Holding SE  DMPG.DE :
    * BOARD OF MANAGEMENT CONFIRMS OUTLOOK FOR 2023 OVERALL AND
EXPECTS REVENUE AND ADJUSTED EBITDA AT UPPER RANGE OF FORECAST
    * Q3 ADJUSTED CONSOLIDATED EBITDA MARGIN AT 28.1%
    * Q3 THE UNADJUSTED EBITDA AMOUNTS TO EUR 208.4 MILLION
(PRIOR-YEAR PERIOD: EUR 231.9 MILLION)
    * Q3 UNADJUSTED EBITDA MARGIN AMOUNTS TO 24.0% (PRIOR-YEAR
PERIOD:
31.6%)

Source text for Eikon:  ID:nEQ5Y5BnDa 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))